When should we test for voltage-gated potassium channel complex antibodies? A retrospective case control study

Journal of Clinical Neuroscience

Volumn 33, Issue , 2016, Pages 198-204

  O'Sullivan, B J ^a   Steele, T ^a   Ellul, M A ^a,b   Kirby, E ^a   Duale, A ^a   Kier, G ^a   Crooks, D ^a   Jacob, A ^a   Solomon, T ^a,b   Michael, B D ^a,b,c  

^a THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autoimmune; Clinical features; Diagnosis; Encephalitis

Indexed keywords

ALKALINE PHOSPHATASE; AUTOANTIBODY; SODIUM; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL COMPLEX ANTIBODY; BIOLOGICAL MARKER; VOLTAGE GATED POTASSIUM CHANNEL;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; BIOCHEMICAL ANALYSIS; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; DYSTONIA; FACIOBRACHIAL DYSTONIC MOVEMENT; FEMALE; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SENSITIVITY AND SPECIFICITY; SODIUM BLOOD LEVEL; VGKC DISEASE; ADOLESCENT; BLOOD; IMMUNOLOGY; MIDDLE AGED; PREDICTIVE VALUE; SEIZURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; DYSTONIA; FEMALE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; POTASSIUM CHANNELS, VOLTAGE-GATED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEIZURES; YOUNG ADULT;

EID: 84979663108     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2016.04.021     Document Type: Article

References (36)

1. [1] Sinha, S., Newsom-Davis, J., Mills, K., et al. Autoimmune aetiology for acquired neuromyotonia (Isaac's syndrome). Lancet 338 (1991), 75–77.
2. [2] Newsom-Davis, J., Mills, K.R., Immunological associations of acquired neuromyotonia (Isaac's syndrome). Report of five cases and literature review. Brain 116 (1993), 453–469.
3. [3] Shillito, P., Molenaar, P.C., Vincent, A., et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 38 (1995), 714–722.
4. [4] Hart, I.K., Acquired neuromyotonia: a new autoantibody-mediated neuronal potassium channelopathy. Am J Med Sci 319 (2000), 209–216.
5. [5] Hart, I.K., Maddison, P., Newsom-Davis, J., et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 (2002), 1887–1895.
6. [6] Buckley, C., Vincent, A., Autoimmune channelopathies. Nat Clin Pract Neurol 1 (2005), 22–33.
7. [7] Irani, S.R., Vincent, A., Autoimmune Encephalitis – new awareness, challenging questions. Discov Med 11 (2011), 449–458.
8. [8] Granerod, J., Ambrose, H.E., Davies, N.W., et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 10 (2010), 835–844.
9. [9] Kleopa, K.A., Autoimmune channelopathies of the nervous system. Curr Neuropharmacol 9 (2011), 458–467.
10. [10] Vincent, A., Irani, S.R., Caspr2 antibodies in patients with thymomas. J Thorac Oncol 5 (2010), 277–280.
11. [11] Irani, S.R., Alexander, S., Waters, P., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 (2010), 2734–2748.
12. [12] Lai, M., Huijbers, M.G., Lancaster, E., et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9 (2010), 776–785.
13. [13] Lancaster, E., Huijbers, M.G., Bar, V., et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 69 (2011), 303–311.
14. [14] Klein, C.J., Lennon, V.A., Aston, P.A., et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 70 (2013), 229–234.
15. [15] Solomon, T., Michael, B.D., Smith, P.E., et al. Management of suspected viral encephalitis in adults – Association of British Neurologists and British Infection Association National Guidelines. J Infect 64 (2012), 347–373.
16. [16] Michael, B.D., Solomon, T., Seizures and encephalitis: clinical features, management, and potential pathophysiologic mechanisms. Epilepsia 53 (2012), 63–71.
17. [17] Thieben, M.J., Lennon, V.A., Boeve, B.F., et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62 (2004), 1177–1182.
18. [18] Vincent, A., Buckley, C., Schott, J.M., et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127 (2004), 701–712.
19. [19] Irani, S.R., Buckley, C., Vincent, A., et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 71 (2008), 1647–1648.
20. [20] Irani, S.R., Pettingill, P., Kleopa, K.A., et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 72 (2012), 241–255.
21. [21] Klein, C.J., Lennon, V.A., Aston, P.A., et al. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 79 (2012), 1136–1144.
22. [22] Tan, K.M., Lennon, V.A., Klein, C.J., et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 70 (2008), 1883–1890.
23. [23] Irani, S.R., Michell, A.W., Lang, B., et al. Faciobrachial dystonic seizures precede LGI1-antibody limbic encephalitis. Ann Neurol 69 (2011), 892–900.
24. [24] Bien, C.G., Scheffer, I.E., Autoantibodies and epilepsy. Epilepsia 52 (2011), 18–22.
25. [25] Vincent, A., An update on antibody-mediated diseases. Adv Clin Neurosci Rehabil 10 (2010), 8–11.
26. [26] Paterson, R.W., Zandi, M.S., Armstrong, R., et al. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 85 (2014), 625–630.
27. [27] Zuliani, L., Graus, F., Giometto, B., et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 83 (2012), 638–645.
28. [28] Montojo, M.T., Petit-Pedrol, M., Graus, F., et al. Clinical spectrum and diagnostic value of antibodies against the potassium channel-related protein complex. Neurologia 30 (2015), 295–301.
29. [29] Huda, S., Wong, S.H., Pettingill, P., et al. An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. J Neurol 262 (2015), 418–424.
30. [30] Randomness and Integrity Services Ltd. RANDOM.ORG. [Computer program]. Dublin, Ireland. Available from: < http://www.random.org>. Accessed 16th October 2014.
31. [31] von Elm, E., Altman, D.G., Egger, M., et al. STROBE initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
32. [32] Majoie, H.J., de Baets, M., Renier, W., et al. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 71 (2006), 135–141.
33. [33] Newey, C.R., Sarwal, A., Hyponatraemia and voltage gated potassium channel antibody associated limbic encephalitis. Neurol Neurophysiol 5 (2014), 1–3.
34. [34] Cros, D., Pearson, C., Verity, M.A., Polymyositis-dermatomyositis: diagnostic and prognostic significance of muscular alkaline phosphatase. Am J Pathol 10 (1980), 159–176.
35. [35] Bhatti, S.F., Vanhaesebrouck, A.E., Soens, I.V., et al. Myokymia and neuromyotonia in 37 Jack Russell terriers. Vet J 189 (2001), 284–288.
36. [36] Liguori, R., Vincent, A., Clover, L., et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124 (2001), 2417–2426.